CTTNBP2NL

Across TCGA pan-cancer cohorts, CTTNBP2NL mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CTTNBP2NL data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTTNBP2NL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CTTNBP2NL expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where CTTNBP2NL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.635	0.854	<.001	41	view →
HNSC	OS	Median	IV	0.849	0.589	.005	35	view →
CCRCC	OS	Quartile	III,IV	1.000	0.548	.006	14	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CTTNBP2NL–PDAC (DFS)

Open the PDAC breakdown →